Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/57787
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2028-12-31
Colecciones
- INI - Artigos de Periódicos [3460]
Metadatos
Mostrar el registro completo del ítem
SUBACUTE PROGRESSION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE I-ASSOCIATED MYELOPATHY/TROPICAL SPASTIC PARAPARESIS
Afiliación
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. The Reference Center on Neuroinfections and HTLV. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. The Reference Center on Neuroinfections and HTLV. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. The Reference Center on Neuroinfections and HTLV. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. The Reference Center on Neuroinfections and HTLV. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Virology Laboratory. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. The Reference Center on Neuroinfections and HTLV. Rio de Janeiro, RJ, Brazil.
Resumen en ingles
Although human T-lymphotropic virus type I (HTLV-I)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) is usually described as a chronic disabling disease, a rapid course over months or even weeks has been reported in some patients. The authors describe the clinical features of HAM/TSP in a Brazilian cohort and evaluate the prevalence of patients with a subacute progression of the disease. This was defined as the requirement of a wheelchair during the first 2 years after the onset of symptoms. Patients with this subacute course and patients with the chronic clinical course were compared in terms of their HTLV-I proviral loads (PLs) using real-time polymerase chain reaction (PCR). Seven out of 88 patients (7.9%) had a subacute progression. All patients were women and 5/7 acquired HTLV-I through sexual contact. There was no significant difference in the real-time PLs between the group with subacute evolution (mean 8.5 copies/100 cells, range 6.03 to 12.09) and those patients with a typical course of disease (mean 11.34 copies/100 cells, range 0.4 to 67.72) (P = .68), suggesting that factors other than the number of infected cells are implicated in the development of such an aggressive course of disease. Early recognition of this subgroup is important because immunosuppressive treatment might be beneficial if instituted promptly.
Compartir